


carestar.com.sg

COVID-19 ESSENTIALS

# WE ARE PROVIDER OF COVID-19 ESSENTIAL CARE ITEMS





is committed to provide COVID-19 essential items with high quality & speed-to-availability

# **FEATURED PRODUCTS**

- DISPOSABLE MASK (3-PLY) & KN-95 MASK

  Most needed almost by everyone in the midst of

  COVID-19 pandemic situation
- COVID-19 TEST KIT
  Most needed Colloidal Gold Method COVID-19 TEST
  KIT Product for instant 15 mins early detection check
- 3 COVID-19 PCR KIT

  Most needed by hospital and lab COVID-19 patients for nasal swab





FOR CIVILIAN USE

carestar.com.sg







**50-PIECE PER BOX** 









**40 BOXES OF 50PCS MASK PER CARTON** 





# **3-PLY FACE MASK**





OUTER (FRONT)

INNER (BACK)

COVID-19 ESSENTIALS



# **PROTECTION FROM**



# 口罩使用说明

使用正确的佩戴方式效果更好

















Build health Quality life

# 好品质 出色源自我们的用心





呵护呼吸健康

Protect breathe



轻薄透气

Light & breathable



Feather filling



吸附异味 Feather filling



+

阻隔细菌污染

Barrier Bacteria



COVID-19 ESSENTIALS

# 医用材质 防尘透气 甄选医用材料 蜂巢设计 易呼吸

CE CERTIFIED

# Certificate of Compliance

No. 4G200325T.HJP0T80



Certificate's Holder:

B

C

ertifi

明書

쪮

ертификат

C

at

ertific

Hebi Junjianan Purificantion Technology Co., Itd.

200 meters North of the intersection of Songshan Road and Yanhe Road, Hebi city, Henan Province,

P. R. C

Certification ECM Mark:



Product: Model(s): Disposable Face Mask

J20

Verification to:

Standard:

EN 149:2001+A1:2009

related to CE Directive(s):
R 2016/425 (Personal Protective Equipment)

Remark: This document has been issued on a voluntary basis and upon request of the manufacturer. It is our opinion that the technical documentation received from the manufacturer is satisfactory for the requirements of the ECM Certification Mark. The conformity mark above can be affixed on the products accordingly to the ECM regulation about its release and its use.

Additional information and clarification about the Marking:



The manufacturer is responsible for the CE Marking process. This document has been issued on the basks of the regulation on EGM Voluntary Mark for the certification of products, RGO1\_ECM rev.3 available at: www.entecerma.it

Issuance date: 25 March 2020

Expiry date: 24 March 2025



Approver ECM Service Director Luca Bertonni

COVID-19 ESSENTIALS

Ente Certificazione Macchine Srl

Via Ca' Bella, 243 – Loc. Castello di Serrayalle – 40053 Valsamoggia (BO) – ITALY 2 +39 051 6705141 ♣ +39 051 6705156 ☑ info@entecerma.lt € www.entecerma.lt



# FDA CERTIFIED





#### Fiscal Year 2020

#### **CERTIFICATION OF REGISTRATION**

This certifies that:

# Hebi Junjianan Purification Technology Co.,Ltd 200 meters North of the intersection of SongShan Road and YanHe Road

Was registered with US Food and Drug Administration, Center for Devices and Radiological Health, pursuit to the Code of Federal Regulations 21 CFR 807, by DongGuan TIS testing technology Co., LTD.

Owner/Operator Number: 10063545

Device Listing#: See annex

Expiration Date: December. 31, 2020

2020 TIS will confirm that such registration remains effective upon request and presentation of this certificate until the end of the calendar year stated above, unless said registration is terminated after issuance of this certificate. TIS makes no other representations or warranties, nor does this certificate make any representations or warranties to any person or entity other than the named certificate bolder, for whose sole benefit it is issued. This certificate does not denote endorsement or approval of the certificate-bolder's device or stablishment by the U.S. Food and Drug Administration. TIS assumes no liability to any person or entity in connection with the foregoing.

Pursuant to 21 CFR 807.39, "Registration of a device establishment or assignment of a registration number does not in any way denote approval of the establishment or its products. Any representation that creates an impression of official approval because of registration or possession of a registration make is misleading and constitutes misbranding." The U.S. Food and Drug Administration does not issue a certificate of registration, nor does the U.S. Food and Drug Administration recognize a certificate of registration, TIS is not affiliated with the U.S. Food and Drug Administration.









# **TEST REPORT**

	TEST REPORT					
	EN 149					
Respiratory protective devices - Filtering half masks to protect						
against pa	rticles - Requirements, testing, marking					
Report Reference No	BD-PPE209305					
Tested by (name + signature):						
Compiled by (name + signature):						
Approved by (name + signature):						
Date of issue	Mar. 13, 2019					
Total number of pages:	6 Pages					
Testing Laboratory						
Address						
Testing location	As above					
Applicant's name	Hebi Junjianan Purificantion Technology Co., Ltd					
Address	200 meters North of the intersection of Songshan Road and Yanhe Road, Hebi city, Henan Province, P. R. C					
Test specification:						
Standard:	EN 149:2001+A1:2009					
Test procedure:	Type approved					
Non-standard test method	N/A					
Test item description	Disposable Face Mask					
Trade Mark:	7 1/A CD					
	之 君健安					
Manufacturer	Hebi Junjianan Purificantion Technology Co., Ltd					
Address:	200 meters North of the intersection of Songshan Road and Yanhe Road, Hebi city, Henan Province, P. R. C					
Model/Type reference:	J20					

Tests performed (name of test and test clause):	Testing location:
All clauses.	10 buildings 1-5 floors of Xinligang Bay Industrial Zone, Huangtian Street, Baoan District, Shenzhen
Test item particulars	<u> </u>
Relative Humidity	: 56% RH
Air Pressure	: 97.9 kPa
Temperature by measurement	: 25 °C
Information for safety use	: N/A
Possible test case verdicts:	
<ul> <li>test case does not apply to the test object</li> </ul>	: N/A
<ul> <li>test object does meet the requirement</li> </ul>	: P (Pass)
<ul> <li>test object does not meet the requirement</li> </ul>	: F (Fail)
Testing:	
Date of receipt of test item	: Mar. 05, 2020
Date (s) of performance of tests	: Mar. 05-13, 2020
"(See Enclosure #)" refers to additional information "(See appended table)" refers to a table appended to Throughout this report a comma (point) is used as the	nout the written approval of the Issuing testing laboratory appended to the report. the report. he decimal separator.
List of test equipment must be kept on file and availa	
List of test equipment must be kept on file and available.  General product information:	

	EN 149		
Clause	Requirement - Test	Result - Remark	Verdict
4	Description		ГР
5	Particle filtering half masks are classified according to their filtering efficiency and their maximum total inward leakage.	FFP2	Р
6	Particle filtering half masks meeting the re- quirements of this European Standard shall be designated in the following manner		Р
7	Requirements		Р
7.1	In all tests all test samples shall meet the require- ments.		Р
7.2	Unless otherwise specified, the values stated in this European Standard are expressed as nominal values		Р
7.3	The visual inspection shall also include the marking and the information supplied by the manufacturer.		Р
7.4	Particle filtering half masks shall be offered for sale packaged in such a way that they are protected against mechanical damage and contamination before use.		Р
7.5	Materials used shall be suitable to withstand han- dling and wear over the period for which the particle filtering half mask is designed to be used.		Р
7.6	If the particle filtering half mask is designed to be re-usable, the materials used shall withstand the cleaning and disinfecting agents and procedures to be specified by the manufacturer.		P
7.7	The particle filtering half mask shall undergo practi- cal performance tests under realistic conditions.		Р
7.8	Parts of the device likely to come into contact with the wearer shall have no sharp edges or burrs.	No sharp edges and burrs	Р
7.9	Leakage		
7.9.1	The laboratory tests shall indicate that the particle filtering half mask can be used by the wearer to protect with high probability against the potential hazard to be expected.	11 %	Р
7.9.2	he penetration of the filter of the particle filtering half mask shall meet the requirements of Table 1.	FFP2	Р
7.10	Materials that may come into contact with the wear- er's skin shall not be known to be likely to cause ir- ritation or any other adverse effect to health.		Р
7.11	The material used shall not present a danger for the wearer and shall not be of highly flammable nature.		Р
7.12	The carbon dioxide content of the inhalation air (dead space) shall not exceed an average		Р





# **TEST REPORT**

EN 149						
Clause	Requirement - Test	Result - Remark	Verdict			
7.13	The head harness shall be designed so that the particle filtering half mask can be donned and removed easily.		Р			
7.14	The field of vision is acceptable if determined so in practical performance tests.		Р			
7.15	A particle filtering half mask may have one or more exhalation valve(s), which shall function correctly in all orientations.		Р			
7.16	The breathing resistances apply to valved and valveless particle filtering half masks and shall meet the requirements of Table 2.	Inhalation: 0.5 Exhalation: 2.1	Р			
7.17	Clogging		Р			
7.17.1	For single shift use devices, the clogging test is an optional test.		Р			
7.17.2	Breathing resistance		P			
7.17.2.1	Valved particle filtering half masks	3 mbar	Р			
7.17.2.2	Valveless particle filtering half masks	3 mbar	Р			
7.17.3	Penetration of filter material		Р			
7.18	All demountable parts (if fitted) shall be readily connected and secured, where possible by hand.		Р			

Test	Required level	Test Date	Average value
Paraffin Oil penetration	<6% after 120mg exposure	Mar.12,2020	5,23%
NaCl penetration	<6% after 120mg exposure	Mar.12,2020	0,73%
Facial leakage	46 results≤11% 8 averages in 10≤8%	Mar.12,2020	Compliant
Air permeability inhalation 30l/min	≤0,7 mbars	Mar.11,2020	0,15 mbar*
Air permeability inhalation 95l/min	≤2,4 mbars	Mar.11,2020	0,65 mbar*
Air permeability exhala- tion 160l/min	≤3 mbars	Mar.10,2020	1,19 mbar*
Carbon dioxide content	<1,0%	Mar.10,2020	0,60%
Flammability	Must not burn or continue to burn for more than 5 seconds after the with- drawal of the flame	Mar.10,2020	Compliant

#### Remark

Protection(D): protection against solid and liquid aerosols, combined with resistance higher to clogging tested with dolomite dust

\*Average of the test results (Receiving State + Simulated port processing)



(FOR CIVILIAN USE WITH PFE 95%)

carestar.com.sg







**10-PIECE PER BOX** 




**BACK VIEW** 



FRONT VIEW



# **KN95 PROTECTION MASK**









# **KN95 PROTECTION MASK**







FOLDED VIEW

LEFT VIEW

**RIGHT VIEW** 





# CERTIFICATION FROM CHINA NATIONAL HEALTH INSPECTION



# 消毒产品生产企业卫生许可证

粤卫消证字[2019]-03-第0007号

单 位 名 称:珠海美茵护理用品有限公司

法定代表人(负责人):朱云

注 册 地 址:广东省珠海市金湾区联港工业区创业西路一号6号厂房

生产地址:广东省珠海市金湾区联港工业区创业西路一号6号厂房

生产方式: 生产

生产项目: 卫生用品

生产类别:卫生巾、卫生护垫、尿裤、尿布(垫、纸)、隔尿垫

有效期限: 2019年09月29日至 2023年09月28日

注:本许可证只对许可批准时的生产条件负责,不是对企业所生产产品的许可,不代表对企业生产产品卫生质量的认可,应在卫生许可证有效期届满前30个工作日之前提出延续申请。

批准日期







# CE CERTIFIED







# **Certification of Conformity**

### PERSONAL PROTECTIVE EQUIPMENT - (EU) 2016/425

Registration No.: ENC2003141GZ85

: Foshan Ipartner Trading Co.,Ltd.

: No.1814 Building 2 Jinse Lingyu Plaza No.1 Foping Raod 3

Guicheng Street Nanhai Foshan

Self priming filter type anti-particle respirator protective face

N95, KN95, F9051, F9052, F1688, F001, F002, F118, F128

F168, F188, F198

Protective mask

Protective mask cup type

Protective mask butterfly type

Zhuhai Meiyin Nursing Products Co., Ltd.

No.6.1st West Chuangye Road, Shuanglin Area, Llanigang

Industrial Zone, Jinwan Area, Zhuhai, Guangdong,

The submitted products have been tested by us with the listed standard and found in compliance with the following European Standards:

Directive	Applied Standards	Test Report No.
PPE (EU) 2016/425	EN 149:2001+A1:2009	ENC2003141GZ85E1

This certificate is based on an evaluation of a sample of the above mentioned product. Technical report and documentation are at the licence applicant's disposal. This certificate does not imply assessment of the series-production of the product. The CE markings as shown below can be affixed on the product after preparation of necessary technical documentation.



#### East Notice Certification Service Co., Ltd.

1/F, Haohui Commercial Bullding, Zhuji Street, Dongpu Town, Tianhe District, Guangzhou City Tel:+86-020-8256-8534 Fax:+86-020-8256-8534 E-mail:enc@enc-lab.com Web: www.enc-lab.com

# FDA CERTIFIED

(USA APPROVED STANDARD)















# Fiscal Year 2020 CERTIFICATION OF REGISTRATION

This centiles that:

### ZHUHAL MEIYIN CARE PRODUCTS CO., LTD.

No.1 Chuangye West Road, Shuanglin Area, Liangang Industrial Zone Zhuhai, Guangdong, 519000, CHINA

has completed the FDA Establishment Registration has manufacturer, foreign exporter) and Device Listing with the US Food & Drug Administration, through

U.5. Agent for FDA. Communications: SUNGO TECHNICAL SERVICE INC.

6050 W EASTWOOD AVE APT 201, CHICAGO,

ILLENOIS 60630, USA

Tolaphone: +1-855-057-7779-715-mail: sungri-group@yatsoc.com

Owner/Operator Number: 10064537 Device Listing#: See annex

SUPGO Technical Service his, will confirm that such registration countries effective again request and presidential in the confirmation of the coloridar year matrix observe, which and registration is contained of the coloridar year matrix observe, which and registration is contained of the confirmation of the contained of the confirmation of the contained of the confirmation of the c

Pressure to 21 CFR 187.79. Registration of a derive exactlishment or assignment of a registration teacher does not be used in a consistency of the extensive of the extensive of the registration of the state consists of a registration or procession of official dispersed because of registration or procession of a registration with the state and procession of a registration or procession of a registration of procession of a registration of procession of a registration of the teacher of the state of the registration, and does the U.S. Food and Drug Administration recipies a conflicted of registration. SURGIN Technical Receives to: to use affiliated with the U.S. Food and Drug Administration.







# **TEST REPORT**











No. FZ2005137

### **TEST REPORT**

Commissioned by 生产单位

样品名称 Name of Sample

型号规格 Type, Specification 检测类别 Testing Purpose

珠海美茵护理用品有限公司 Zhuhai Meiyin Care Products Co., Ltd

珠海美茵护理用品有限公司

Zhuhai Meiyin Care Products Co., Ltd

Butterfly type disposable face mask (N95) 鹰 嘴蝶形无骨 N95 口罩

委托检测 Commission



### No. FZ2005137

# GUANGDONG TESTING INSTITUTE OF PRODUCT QUALITY SUPERVISION

TEST

REPORT

报告随机号 Security Code: JN00361 第1页 共5页

样品名称 Name of Sample	Butterfly type disposable face mask (N95) 鹰嘴螺形无骨 N95 口學 送样(J) 抽样(/)		样品编号 Sample number	YFZ20/005137	
7007	Sending	sampling			
商标	李丽	Meivin	型号规格	WY002	
Trade mark		INTO CONTROL OF THE PROPERTY O	Type, Specification		
委托方		理用品有限公司	检测类别	委托检测	
Commissioned by		re Products Co., Ltd	Testing Purpose	Commission	
委托方地址 Address of client	No. 6, 1St West Shuanglin Area, L	珠海市金湾区联港工业区双林片创业西路 一号 6 号厂房 No. 6, 15t West Chuangye Road, Shuanglin Area, Lian' gang Industrial Zone, Jinwan Area Zhuhai, Guangdong,			
生产单位		理用品有限公司	抽样单编号	5486	
Factory		re Products Co., Ltd	Sampling list No		
受检单位			生产日期		
Inspected unit		7.7.7	Date of manufacture		
抽样单位			样品数量	40(个)	
Sampling unit			Quantity of sample	40 (Piece)	
抽样地点			抽样基数		
Location of sampling			Basic quantity of sampling		
抽样日期		0.00	检验地点	本部实验室	
Date of sampling			Location of testing	Laboratory	
收样日期	anna he	on the same	检验日期	2020年03月03日~	
Date of receiving	2020 年	03月03日	Date of testing	2020年03月10日	
检测依据 Testing reference		股防护用品 自吸过滤式 iratory protective eq			
判定依据					
Judging reference					
检测结论 Remarks	見检測結果 Test resul	K. ts are attached as be	olov.	WE THE STATE OF TH	
备注 Notes		示此項不适用,报告中 s that this item is not applicab	The state of the s	(01)	

No. FZ2005137



第2页 共5页

序 号 No	檢辦項目[单位] Test items[Unit]	标准条款 Standard terms	特強整複數专用章 Standard requirements	松湖i Resi		单项结论 Conclusion	备注 Notes
1160					99.6		
				99.4			
				99.5			
					99.4		
				未预处理	99, 4		
				Unpretreated	99.4		
					99.5	合格 Pans	
			KN95 ≥ 95.0		99.5		
1	过滤效率[%]	过滤效率[8] 5.3 thering efficiency			99.6		7
	Filtering efficiency				99.4		1.00
			9	和处理 Pretreated	99.3		
					98.9		
					99.0		
					99.1		
					99.3		
	eg.		氯化钠颗粒物检测 Detection of oily particles 温度 Temperature: (25±5)℃ 湿度 Humidity: (30±10)%	实测温度 Mea temperature: 实测湿度 Mea Humidity: (3	(23~25) ℃ sured		
				未预处理	60.6		
	吸气阻力[Pa]	』 息吸气阻力≤350	Unpretreated	60.2	合格		
2	Inhale resistance	5. 5	Total inhale resistance≤350	预处理	65. 7	Pass	1
				Pretreated 62. 5	1		
		跨气阻力[Pa] Edulation 5.5 Total exhalation resistance ≤250 預处理 67			62, 0	合格	
					64.2		
			67.4	Pass	1		
			1.00		Pretreated	65.8	



# **TEST REPORT**



序 号 No	检测项目[单位] Test items[Unit]	标准条款 Standard terms	檢驗整測专用章 Standard requirements		J结果 sult	単项结论 Conclusion	為注 Notes
4	死腔[%] Dead cavity	5.7	以吸入气中二氧化碳体积分数 表示时,结果平均值应≤1 When expressed as the volume fraction of curbon dioxide in the inhaled air, the average value of the results should be ≤1	平均值A	verage: 0.8	合格 Pass	1
			可更换式半面罩在规定检测条 件下,可更换式过滤元件与面 罩之间的所有连接和连接部	未預处理 Unpretreated			
5	连接和连接部件 links and connected components	5. 10	件,在承受 50N,持续时间 10s 的轴向拉力时,不应出现滑 股,斯黎或变形 When inspecting the half mask in accordance with regulations, all links and connected components between the replaceable filter element and the mask should not slip, break or deform when subjected to an axial tensile force of 50N for 10s	预处理 Pretreated	无此部件, 此项不检 Without this part, this item is not detected		1
22	可燃性	可燃性 5. 13 After being removed from the fl parts exposed to the flame to burn. If burning, the after burn	無理 5. 13 After being removed from the flame, the parts exposed to the flame should not burn. If burning the after burning time file # Unburned		燃烧现象 Unburned 未出现 燃烧现象	合格	
6	Flammability			parts exposed to the flame should not	燃烧现象 Unburned	Pass	1
			should not exceed 5s	Pretreated	未出現 燃烧现象 Unburned		



# No. FZ2005137 第5页 共5页 附注 APPENDIX: 1、试验地点 Place of test: 广州市黄埔区科学城科 2、委托单位地址及銀編 Add.&Postcode: 珠海市金湾区联港工业区双林片创业西路一号6号广房 No.6,1St West Chuangye Road, Shuanglin Area, Lian' gang Industrial Zone, Jinwan Area Zhuhai, Guangdong. 3、检测环境条件 Testing ambient conditions: 检测项目均在相应标准规定的条件下进行(有注明的除外)The test items shall be carried out under the conditions specified in the corresponding standards (Unless otherwise noted) 4、抽样程序(如适用)Sampling procedure (if applicable): \_\_\_\_ 5、偏离标准方法的说明(如适用)Statement of deviating standard method ( if applicable): \_\_\_ 6、检测结果不确定度说明(如适用)Uncertainty statement of test results ( if applicable): \_\_\_\_ 7。分包项目及分包方(如适用)Subcontracted items and subcontractors ( if applicable): \_\_\_\_





(FOR CIVILIAN USE WITH PFE 95%)

carestar.com.sg





# **KN95 3D FRONT VIEW**



# **KN95 3D SIDE VIEW**







# **FRONT**











# INDIVIDUALLY PACKED FRONT

**BACK** 





# **CE CERTIFICATION**





# Certificate

#### No. ICR Polska/6301197

 $\epsilon$ 

Name and address of certificate owner: Jinjiang Heng'an Household Tissue Products Co., Ltd Wuli Industrial Zone, Anhai Town, Jinjiang, Fujian P.R. China

Name and address of manufacturer:

Jinjiang Heng'an Household Tissue Products Co., Ltd Wuli Industrial Zone, Anhai Town, Jinjiang, Fujian P.R. China

Product name: KN95 MASK
Product types: XCL010, XCX010

Product trademark: n/

This certificate confirms that the product meets the requirements of the following standards and within limits of its standards gives presumption of conformity with essential requirements of Regulation 2016/425

EN 149:2001+A1:2009

The certification process has been carried out in accordance with the program PC-P-07-07. Evaluation has been carried out in accordance with test reports made by Monotek Technical Service Company Limited

No. of test reports: MT20200310-018-A

Certificate issue date: 19.03.2020 Expiration date: 18.03.2025

The mutual obligations and rights of the certification are regulated by the contract No. ICR Polska/2020-3109.

This certificate applies to products having the same attributes (parameters), intended use, that have been evaluated and meet the requirements of the aforementioned standard.





Director: Rafał Kalinowski

Warsaw, 19, 03, 2020



ICR Polska Co. Ltd.

ul. Plac Przymierza 6, 03-944 Warszawa www.icrpolska.com, e-mail; icrpolska@icrqa.com



# **TEST REPORT**

Monotek Technical Service Company Limited Page 1 of 10 Report No. MT20200310-018-A

### Test Report

Client Name : Jinjiang Heng'an Household Tissue Products Co.,Ltd Wull Industrial Zone, Anhai Town, Jinjiang, Fujian P.R.China Address Product Name KN95 MASK

Issued by : Monotek Technical Service Company Limited

Mar. 19, 2020

### Monotek Technical Service Company Limited Page 2 of 10 Report No. MT20200310-018-A

Respiratory protective	EST REPORT EN 149 e devices — Filtering half masks t	o protect against particles —
	Requirements, testing, marki	
Report reference No	: MT20200310-018-A	1 10
Complet by (+ signature)	: Tony Xiao	long was
Approved by (+ signature)	: Barry Zhou	Tony Das Barry Zhou
Date of issue	: Mar. 19, 2020	- J
Contents	1 10	
	Monotek Technical Service C	
	Building A. No. 3, Huafa Rose Guangdong, China,	d, Longgang District, Shenzhen,
Testing location	: Same as above	
	Jinjiang Heng'an Household 1	
Address	: Wull Industrial Zone, Anhai To	own, Jinjiang, Fujian P.R.China
Test specification		
Standard	: EN 149:2001+A1:2009	
Test procedure	: CE Certification	
Procedure deviation	: NA.	
Non-standard test method	NA.	
Type of test object		
Description	KN95 MASK	
Trademark	: N.A.	
Modelitype reference	: XCL010, XCX010	
Manufacturer	: Same as applicant	
Address	: Same as applicant	

#### Monotek Technical Service Company Limited Page 3 of 10 Report No. MT20200310-018-A

Possible test case verdicts	
- test case does not apply to the test object	: N (Not applicable)
- test object does meet the requirement	P (Pass)
- test object does not meet the requirement	: F (Fail)
Testing	
Date of receipt of test item	: Mar. 16, 2020
Date(s) of performance of test	Mar. 16, 2020 to Mar. 19, 2020
General remarks	
The test results presented in this report relate only to	o the object tested.
This report shall not be reproduced except in full wit	hour the written approval of the testing laboratory



#### Monotek Technical Service Company Limited Page 4 of 10 Report No. MT20200310-018-A

	EN 149		
Clause	Requirement – Test	Result - Remark	Verdic
5	Classification		P
	Particle filtering half masks are classified according to their filtering efficiency and their maximum total inward leakage. There are three classes of devices: FFP1, FFP2 and FFP3.	FFP2	e
6	Designation		P
	Particle filtering half masks meeting the requirements of this European Standard shall be designated in the following manner: Particle filtering half mask EN 149, year of publication, days, option.		P
7	Requirements		P
7.1	General		P
	In all tests all test samples shall meet the requirements.	(	P
7.2	Nominal values and tolerances		P:
	Unless otherwise specified, the values stated in the European Standard are expressed as nominal values. Except for temperature limits, values which are not stated as mexime or minims shall exabject to a tolerance of ± 5 %. Unless otherwise specified, the ambient temperature for testing shall be (16 - 32) °C, and the temperature limits shall be subject to an accuracy of ± 1 cancuracy for the size of the subject to an accuracy of ± 1 cancuracy for the size of the subject to an accuracy of ± 1 cancuracy for ± 1 cancuracy f		Р
7.3	Visual inspection		P
	The visual inspection shall also include the marking and the information supplied by the manufacturer.	Ü	Р
7.4	Packaging		P
	Particle filtering half masks shall be offered for sale packaged in such a way that they are protected against mechanical damage and contamination before use. Testing shall be done in accordance with 8.2.		Pi
7.5	Material		P
	Materials used shall be satable to withstand handling and wear over the period for which the handling and wear over the period for which the particle filtering half mask is designed to be used. After undergoing the conditioning described in 8.3.1 note of the particle filtering half masks shall have soffered mechanical fallace of the faceprice tassets. Three particle filtering half masks whall not seem to be seen to the seem of the 8.3.2 the perticle filtering half mask whall not cortapae. Any maintail from the filter madial retexact by the air flow through the filter shall not Testing shall be done in accordance with 8.3.1 and Testing shall be done in accordance with 8.2.1.	No mechanical failure of the facepice or strape.  Not constituted a hazard or nuisance for the wearer.	P
7.6	Cleaning and disinfecting		N





# **TEST REPORT**

#### Monotek Technical Service Company Limited Page 5 of 10 Report No. MT20200310-018-A

	EN 149		
Clause	Requirement – Test	Result - Remark	Verdic
	If the particle filtering half mask is designed for to be re-usable, the materials used shall withstand the cleaning and disinfecting agents and procodures to be specified by the manufacturer. Testing shall be done in accordance with 8.4 and 8.5. With reference to 7.9.2, after cleaning and disinfecting the re-usable particle filtering half mask shall satisfy the penetration requirement of the refevent class.		N
7.7	Practical performance		P
	The particle filtering half mask shall undergo- proaclical performance leets under realistic conditions.  These general tests serve the purpose of checking the equipment for imperfections that cannot be detarmined by the tests described belsewhere in this standard. Where practical performance tests show the apparatus has imperfections related to wearrier acceptance, the test house shall provide full details of those parts of the practical performance tests which revealed these imperfections.		Р
7.8	Finished of parts		P
	Likely to come into contact with wearer, no sharp edges or burns	Checked	Р
7.9	Leakage		P
7,9.1	Total inward leakage		Р
	The laboratory tests shall indicate that the particle filtening half masks can be used by the wearer to protect with high probability against the potential hazard to be expected, consists of three. The total inward leakage consists of three. The total inward leakage consists of three caskage (if exhabitation valve filter) and filter penetration. For particle filtering half masks filted in accordance with the manufacturer's information, at least 46 out of the 50 individual secretice results (i.e. filt subjects x 6 secretices) for total inward (i.e. filter) and in a continuation, at least 4.0 out of the 50 individual secretices results and, in addition, at least 8.0 or filt of the filtering and, in addition, at least 8.0 or filt of 51 individual wearer arithmetic means for the total inward leakage shall be not grosself than 8.% for FFPS.	48 out of 50 result: 21% 9 out of 10 means: 22%	P
7.9.2	Penetration of filter material		P
	The penetration of the filter of the particle filtering half mask shall meet the requirements of Table 1.	Sodium chloride 95l/min: 4,8% Paraffin oil test:95l/m; Max:5.0%	Р

#### Monotek Technical Service Company Limited Page 6 of 10 Report No. MT20200310-018-A

		EN 149		
Clause	Require	ment - Test	Result - Remark	Verdict
		Table 1 — Penetration	of filter material	
Classif	ication	(A) Maximum penetrati	on of test aerosol 🗐	
Classification		Sodium chloride test 95 l/min % max.	Paraffin oil test 95 l/min %	
FFP1 FFP2 FFP3		20 6 1	20 6 1	
7.10		alle Miles and alle a killer	E	P
7.10	Materia wearer cause health.	tibility with skin is that may come into contact with the sixin shall not be known to be likely to iritation or any other adverse effect to shall be done in accordance with 8.4 and		P
7.11	Flamma	ability		Р
	When to not burn a after r The par usable is	terial used shall not present a danger for the and shall not be of highly flammable nature, steed, the particle filtering half mask shall no root to continue to burn for more than 5 emoval from the flame. ticle filtering half mask does not have to be after the test. shall be done in accordance with 8.6.	2s after removal from flame	P
7.12	Carbon	dioxide content of the inhalation air		P
	(dead s	foon dioxide content of the inhalation air pace) shall not exceed an average of 1,0 % me). shall be done in accordance with 8.7.		Р
7.13	Head h	arness		P
	particle remove The he adjustin particle capable requirer	ad harmess shall be designed so that the littlering half mask can be donned and dessity.  ad harmess shall be adjustable or self- ag and shall be sufficiently robust to hold the fiftering half mask firmly in position and be of maintaining total inward leakage ments for the device.		Р
7.14	Field of	vision		P
	practica	d of vision is acceptable if determined so in I performance tests. shall be done in accordance with 8.4.	When test in practical performance test, the filed of vision is acceptable	Р
7.15	Exhalat	tion Value		N

#### Monotek Technical Service Company Limited Page 8 of 10 Report No. MT20200310-018-A

	EN 149		
Clause	Requirement – Test	Result - Remark	Verdict
	After clogging the inhalation and exhalation resistances shall not exceed FFP1: 2.1 mbar FFP2: 2.4 mbar FFP2: 2.4 mbar FFP3: 3 mbar at 95 lmin continuous flow.  Testing shall be done in accordance with 8.9	2.31 mbar	P
7.17.3	Penetration of filter material		P
	All types (valved and valveless) of particle Illering half masks claimed to meet the clogging requirement shall also meet the requirements given in 7.9.2, for the Penetration test according to EN149, after the clogging freatment. Testing shall be done in accordance with 8.11 using EN149.		P
7.18	Demountable parts		N
	All demountable parts (if fitted) shall be readily connected and secured, where possible by hand.		N
8	Testing shall be done in accordance with 8.2.		
	Testing		
8.1	General		
8.2	Visual inspection  The visual inspection is carried out where appropriate by the test house prior laboratory or practical performance tests:		1=
8.3	Conditioning		1 8
8.3.1	Simulated wearing treatment		
	A breathing machine is adjusted to 25 cycles/min and 2.0f/stroke, the saturator being set at a temperature in excess of 37°C. The air shall be saturated at (37+/-2)°C at the mouth of the dummin head.		-
	During the test time at appro.20 min intervals the particle filter half mask shall be completely removed from the dummy head and relitted such that during the test period it is fitted ten times to the dummy head.		=
8.3.2	Temperature conditioning		- 1
	Empise the masks to the following thermal cycle: a) for 24h to 4 orly atmosphere of (794-3) °C b) for 24h to a dry atmosphere of (-30+4-3) °C and allow to return to room temperature for at least 4h between exposures and prior to subsequent leading.  The conditioning shall be carried out in a manner		-
0000	which ensures that no thermal shock occurs.		-
8.3.3	Mechanical strength		

#### Monotek Technical Service Company Limited Page 8 of 10 Report No. MT20200310-018-A

	EN 149		
Clause	Requirement - Test	Result - Remark	Verdic
	After clogging the inhalation and exhalation resistances shall not exceed FFP1: 2.1 mean FFP2: 2.4 mean FFP2: 2.4 mean FFP3: 3 mean at 95 lmin continuous flow. Testing shall be done in accordance with 8.9	2.31 mbar	P
7.17.3	Penetration of filter material		P
	All types (valved and valveless) of particle titlering half masks claimed to meet the clogging requirement shall also meet the requirements given in 7.9.2, for the Penetration test according to EM149, after the clogging treatment. Testing shall be done in accordance with 8.11 using EN149.		P
7.18	Demountable parts		N
	All demountable parts (if fitted) shall be readily connected and secured, where possible by hand. Testing shall be done in accordance with 8.2.		N
8	Testing		1 2
8.1	General		- 1 -
8.2	Visual inspection		
0.6	The visual inspection is carried out where appropriate by the test house prior laboratory or practical performance tests.		
8.3	Conditioning		8
8.3.1	Simulated wearing treatment		
	A breathing machine is adjusted to 25 cycles/min and 2.0f/stroke, the saturator being set at a temperature in excess of 37°C. The air shall be saturated at (37+/-2)°C at the mouth of the dummy head.		-
	During the test time at appro.20 min intervals the particle filter half mask shall be completely removed from the dummy head and refitted such that during the test period it is fitted ten times to the dummy head.		=
8.3.2	Temperature conditioning		-
	Exisce the masks to the following themsi cycle: a) for 24h to 4 or 4 misosphere of (704-5) °C b) for 24h to a dry atmosphere of (-30+45) °C and allow to return to room temperature for at least 4h between exposures and prior to subsequent testing. The conditioning shall be carried out in a manner which ensures that no thermal shock occurs.		_





# **TEST REPORT**

#### Monotek Technical Service Company Limited Page 9 of 10 Report No. MT20200310-018-A

	EN 149		
Clause	Requirement – Test	Result - Remark	Verdict
8.3.4	Flow conditioning	T	- 1 - 5
8.4	Practical performance		- 2
8.4.1	General		
8.4.2	Walking test	1	
8.4.3	Work simulation test	-	-
8.5	Leskage	/	-
8.5.1.1	Total inward leakage		
8.5.2	Method		-
8.6	Flammability		-
8.7	Carbon dioxide content of inhalation air		-
8.8	Strength of attachment of exhalation valve housing		-
8.9	Breathing resistance		
8.10	Clogging		
8.11	Penetration of filter material	-:	
9	Marking		
9.1	Packaging	Complied	р
9.2	Particle filtering half mask	Complied	Р
10	Information supplied by the manufacture	Checked	р

Monotek Technical Service Company Limited Page 10 of 10 Report No. MT20200310-018-A





\*\*\*\* End of Report \*\*\*\*





# MEDICAL SURGICAL FACE MASK

(MEDICAL GRADE WITH STERILE, BFE 95% & PFE 30%)

FOR HOSPITAL USE

carestar.com.sg



# PACKED IN STERILE PER 10-PIECE






# MEDICAL SURGICAL FACE MASK

# FOR HOSPITAL USE

# **50-PIECE PER BOX**







# MEDICAL SURGICAL FACE MASK

# FOR HOSPITAL USE



### **EC Declaration of Conformity**



### Regarding Medical Device Regulation (EU)2017/745

#### Manufacturer:

Name: Shandong Zhushi Pharmaceutical Group Co., LTD

Address: No.6 Shande Road Shan County, Heze City, Shandong, China 274300

#### European Authorized Representative:

Name: SUNGO Europe B.V

Address: Olympisch Stadion 24,1076DE Amsterdam, Netherlands

Product:: Name: Face Mask

Model: Bandage type,Fat type,Foldling type,Chil

type;22cm\*9.5cm,20cm\*9cm,18cm\*9.3cm, //.5cm\* 5 , i6.5cm\*9.5cm,1 5\*s.5 n,1

4.5cm\*9cm,12cm87cm;or custor

Classification: Class I

Rule: According to F le 1, Ann. VIII, C apter III I EU Medical Device Regulation

(EU)2017/7

or a mit as assment, roced at nnex II+III

100

ייי עט

Proc	at into	Size	UDI-DI	Product Mod - Size	UDI-DI
- 91					

We confirm our product can meet the requirement of Medical Device Regulation at the following harmonized standards:

EN ISO 14971:2012

EN ISO 15223-1:2016

EN 1041:2008

ISO 10993-1:2018

EN ISO 10993-5:2009

EN ISO 10993-10:2010

EN 14683:2014

Signature:

Position:



# CE CERTIFIED



# FOR HOSPITAL USE

# • GERTIFICA

I I I I I









## Fiscal Year 2020 CERTIFICATION OF REGISTRATION

# 兹证明:

This certifies that: 山东朱氏药业集团有限公司 Shandong Zhushi Pharmaceutical Group Co., Ltd

Shandong Zhushi Pharmaceutical Group Co., Ltd South Fanlou Road, Shan County Development Zone, Heze, Shandong, China 274300

已经通过美国食品药品监督管理局完成了FDA制造商注册和上市

has completed the FDA Establishment Registration (as Manufacturer) and Device Listing with the US Food & Drug Administration, through

U.S. Agent for FDA Communications: SUNGO TECHNICAL SERVICE INC.
6050 W EASTWOOD AVE APT 201, CHICAGO,

ILLINOIS 60630, USA Telephone: +1-855-957-7779 / E-mail: sungo.group@yahoo.com

Registration Number: 3013496867 Device Listing#: See annex

SUNGO Technical Service lue will confirm that such registration remains effective upon request and presentation of this certificate total the end of the calendar year stated above, unless said registration is terminated after insuance of this certificate. SUNGO Technical Service Inc. andees no other representations or warranties to any person or early other than the numed certificate make any representations or warranties to any person or early other than the numed certificate holder, for whose sole benefit it is issued. This certificate does not denote endorsement or approval of the certificate-holder's device or establishment by the U.S. Food and Drug Administration. SUNGO Technical Service Inc. assumes no liability to any person air entity in connection with the foregoing.

Pursuant to 21 CFR 807.39. "Registration of a device extablishment or assignment of a registration number does not it any way denote approval of the establishment or its products. Any representation that creates an impression of official approval because of registration or possession of a registration number is misleading and constitutes misbranding. The U.S. Food and Drug Administration does not issue a certificate of registration, nor does the U.S. Food and Drug Administration recognize a certificate of registration, SUNGO Technical Service Inc. is not affiliated with the U.S. Food and Drug Administration.





# FDA CERTIFIED



COVID-19 ESSENTIALS



# MEDICAL SURGICAL FACE MASK

# FOR HOSPITAL USE

# **TEST REPORT**

#### 医疗器械产品技术要求编号:

### 一次性使用医用外科口罩

#### 1.产品型号/规格及其划分说明

#### 1.1结构、组成

一次性使用医用外科口罩 以下简称:口罩)由表层、中间层、底层、口罩带、 鼻夹组成。

#### 1.2 型号规格

根据临床需要,口罩设计样式为平面耳挂式的,规格为:  $17.5 cm \times 9.5 cn$ ,其具体规格尺寸见表 1 con

		表 1 一次性使用医用外科口重规格尺寸			外山卓规格尺寸
型号规格 长 宽 展开宽			单根口罩带长(每侧各1根)		
	17.5cm×9.5cm	17.5	9.5	17.0	17.0

#### 1.3 材质组成

表层材料为卫生级聚丙烯仿粘布、中间层材料为聚丙烯喷丝法制成的高效过 滤熔喷布、底层材料为卫生级聚丙烯仿粘布、口罩带为涤纶线和少量氨纶线针织 而成、鼻夹为可弯折可定型的聚丙烯制成。

#### 2. 性能指标

#### 2.1 外观

口罩外观应整洁、形状完好、表面不得有破损、污渍。

#### 2.2 结构与尺寸

- 2.2.1 口罩佩戴好后, 应能罩住佩戴者的口、鼻至下颌。
- 2.2.2 规格尺寸应符合表 1 的规定,最大误差不超过±5%。

#### 2.3 鼻夹

- 2.3.1 口置上的配有鼻夹,鼻夹由可塑性材料制成。
- 2.3.2 量卖长度的不小干 8.0cm。

#### 2.4 口置带

- 2.4.1 口置带应戴取方便。
- 2.4.2 每根口罩带与口罩体连接点的断裂强力应不小于 10N。

#### 2.5 合成血液穿透

2mL 合成血液以 16.0kPa(120mmHg)压力喷向口罩外侧面后,口罩内侧面不应 出现渗透。

#### 2.6 讨波效率

#### 2.6.1 细菌过滤效率 (BFE)

口罩的细菌过滤效率应不小于 95%。

#### 2.6.2 颗粒过滤效率 (PFE)

口置对非油性颗粒的过滤效率的不小干 30%。

#### 2.7 压力差(Δ<sub>0</sub>)

口罩两侧面进行气体交换的压力差 $\Delta$ p 的不大于 49Pa/cm²。

#### 2.8 阻燃性能

口置材料向采用不易燃材料,口置离开火焰后燃烧不大干 5s。

#### 2.9 环氧乙烷残留量

采用环氧乙烷灭菌,环氧乙烷残留量应不超过 10 H g/g。

#### 2.10 无菌

口置的无菌。

#### 3. 检验方法

#### 3.1 外观

随机取3个口罩,正常视力或矫正视力检查,应符合2.1的要求。

#### 3.2结构与尺寸

- 3.2.1 随机取 3个口罩,实际佩戴验证,结果应符合 2.2.1 的要求。
- 3.2.1 以通用或专用量具测量,结果应符合 2.2.2 的要求。

#### 3.3 鼻夹

- 3.3.1 随机取 3 个口罩,检查量夹材质并手试查折,均应符合 2.3.1 的要求。
- 3.3.2 随机取 3 个口罩,取出鼻夹,以通用或专用量具测量,均应符合 2.3.2 的要求。

#### 3.4 口罩带

3.4.1随机取3个口罩,通过佩戴检查其调节情况,均应符合2.4.1的要求。

3.4.2 随机取 3 个口罩,以 10N 的静拉力进行测量,持续 5s,均应符合 2.4.2 的要求。

#### 3.5 合成血液穿透

- 3.5.1 样品数量: 取 5 个样品进行试验。
- 3.5.2 預处理条件: 样品在 21℃±5℃, 相对湿度 85%±5%环境试验箱中预处理 至少4h。样品从环境箱中取出 1min 内作测试。
- 3.5.3 按照 YY/T0691-2008 的试验方法进行,合成血液的配制方法见附录。结果 应符合 2.5 的要求。

#### 3.6 讨滤效率

分别随机取 3个口罩,分别按照 YY0469-2011中细菌过滤效率和颗粒过滤效率测试方法进行试验,结果应符合 2.6.1和 2.6.2的要求。

#### 3.7压力差(△p)

随机抽取 5个样品进行试验,按照 YYO469-2011 中压力差测试方法进行试验, 结果应符合 2.7 的要求。

#### 3.8 阳燃性能

随机抽取3个样品进行试验,按照YY0469-2011中阻燃性测试方法进行试验,结果应符合2.8的要求。

#### 3.9 环氧乙烷残留量

环氧乙烷残留量按 GB/T14233.1-2008中规定的方法进行,以第九章规定极限浸提的气相色谱法为仲裁方法,结果应符合 2.9 的规定。

#### 3.10 天菊

按照《中华人民共和国药典》(2015年版 四部) 通则 1101 "无菌检查法" 中的"直接接种法"进行试验,结果应符合 2.10 的要求。

#### 4术语

#### 细菌过滤效率(BFE)

在规定的流量下,口置材料对含菌悬浮粒子滤除的百分数。



# MEDICAL SURGICAL FACE MASK

# FOR HOSPITAL USE

# **TEST REPORT**

#### 附录

#### (资料性附录)

#### 合成血液配制方法

#### 1 试剂

按照如下配方制备 11 合成血液:

羧甲基纤维素钠[例如,CMC-Sigma 9004-32-4 中粘度]

聚氧乙烯(20)山梨糖醇酐单月桂酸酯(例如,吐温 20[Fluka9377]) 0.04g

氯化钠(分析纯) 2.4g

苋菜红染料[例如,Sigma915-67-3](915-67-3)

1.0g

磷酸二氢钾(KHAPOA) 磷酸氢二钠(NaHPO4)

1.2g 4.3g

蒸馏水或去离子水

加至 1L

注 1: 可在合成血液中加入 2-甲基-4-异噻唑啉-3-酮盐酸盐(MIT)(0.5g/L) 以延长溶液的贮存期。

注 2: Sigma 9004-32-4, Fluka 915-67-3以及 Fluka 9377 是合适的商用产 品举例。给出这一信息是为了方便本标准的使用者,并不代表对该产品的认可。

#### 2配制方法

将羧甲基纤维素钠溶解在 0.5L 水中,在磁力搅拌器上混匀 60min。

在一个小烧杯中称量叶温 20, 加入水湿匀。

将吐温 20 溶液加到羧甲基纤维素钠溶液中,用蒸馏水将烧杯洗几次加到前 溶液中。

将 NaCl 溶解在溶液中,将 KH\_PO。和 Na\_HPO。溶解在溶液中。

加入 MIT (如使用) 和苋菜红染料。

用水将溶液稀释近 1000ml。

用磷酸盐缓冲液将合成血液的 pH 调节至 7.3±0.1, 定容至 1000ml。

按照 GB/T5549-1990 测量合成血液的表面张力,结果应是 0.042N/m± 0.002N/mo

### 一次性使用医用外科口罩使用说明书

【产品名称】 一次性使用医用外科口罩

【规格型号】17.5cm×9.5cm 允差: ±5%

【注册人名称】山东朱氏药业集团有限公司

【注册人住所】单县经济技术开发区类楼路南

【联系方式】电话: 0530-4265777

【售后服务单位】 山东朱氏药业集团有限公司

【生产企业名称】 山东朱氏药业集团有限公司

**【生产企业住所**】 单县经济技术开发区类楼路南

【生产企业地址】 山东单县经济技术开发区

【联系方式】电话: 0530-4265777

【生产许可证编号】

【产品注册证编号】

【产品技术要求编号】

**【执行标准号】**YY0469-2011 医用外科□罩

**〖产品性能〗**1.2mL含成血液以 16.0kPa(120mHg)压力喷向口罩外侧面后,口罩内侧面不应 出现渗透; 2.口罩的细菌过滤效率应不小于 95%; 3.口罩对非油性颗粒的过滤效率应不小于 30%;4. 口罩两侧面进行气体交换的压力差点p应不大于49Pa/cm²;5. 口罩材料应采用不易燃 材料,口置离开火焰后燃烧不大于 5s;6. 采用环氧乙烷灭菌,环氧乙烷碳留里应不超过 10 kl g/gi T.口罩应无菌。

**【主要结构组成或者成分】**由表层、中间层、底层、口罩带、鼻夹组成。表层材料为聚丙烯 纺粘布,中间层材料为聚丙烯喷丝法制成的过滤熔喷布、底层材料为聚丙烯纺粘布、口置带 为涤纶线和少量氨纶线针织而成、鼻夹为可弯折可定型的聚丙烯制成。

**【适用范围】供**临床医务人员在有创操作过程中佩带,覆盖住使用者的口、鼻及下颌,为防 止病原体微生物、体液、颗粒物等的直接透过提供物理屏障。

#### 【注意事项、警示】

- 1. 医用外科口罩只能一次性使用:
- 2. 口置潮湿后,应及时更换;
- 3. 每次佩戴医用防护口罩进入工作区域之前,应进行密合性检查;
- 4. 口罩受到患者血液、体液污染后,应及时更换;
- 5. 包装破损后禁止使用;
- 6. 产品开封后应尽快使用;
- 7. 产品使用后应按医疗垃圾相关规定进行处理。

#### 【禁忌症】



#### 【使用说明】

- 1.打开产品包装,取出口罩,将有鼻夹一端向上,有包边一面朝外,轻拉耳带将口罩挂于双 耳,应避免手部接触口罩内侧。
- 2. 轻按鼻夹使其与鼻梁贴合,然后按住鼻夹。将口置下端向下拉至下颌处,使折叠边完全展
- 3. 整理口罩佩戴效果,使口罩能罩住使用者的鼻、口至下颌并保证口罩的密闭性。

【**运输贮存**】运输工具应清洁卫生、隔离火源。本产品应存放在干燥阴凉处,注意防水,避 免阳光直射,严禁与有毒有害物质共同存放。本产品应贮存在阴凉干燥,清洁、避光、无腐 蚀性气体、通风良好的室内。

#### 【生产日期】见单包装

【使用期限】 经环氧乙烷灭菌后,有效期两年。

#### 【标签、包装标识】

*			
	STERILE	无菌	
	STERILEEO	经环氧乙烷灭菌	_
	2	不得二次使用	+
	8	包装破损禁止使用	
		+	κ,

【编制日期】2019年01月30日



# MEDICAL SURGICAL FACE MASK

# FOR HOSPITAL USE

### **TEST REPORT**

#### 最小销售单元标签设计样稿

商标



【产品名称】 一次性使用医用外科口罩

【型号规格】17.5cm×9.5cm 允差: ±5%

【包装】 个/袋

【企业名称】山东朱氏药业集团有限公司

【生产企业住所】单县经济技术开发区类楼路南

**【生产企业地址**】山东单县经济技术开发区

【联系方式】0530-4265777

【售后服务单位】山东朱氏药业集团有限公司

【生产许可证编号】

【产品注册证编号】

【产品技术要求编号】

【执行标准号】YY0469-2011 医用外科口罩

■适用范围3 共临床医务人员在有创操作过程中佩带,覆盖住使用者的口、鼻及下颌,为防止病原体微生物、

体液、颗粒物等的直接透过提供物理屏障。

#### 【使用说明】

- 打开产品包装,取出口罩,将有角夹一端向上,有包边一面朝外,轻拉耳带将口罩挂于双耳,应避免手部接触口墨内侧。
- 2. 轻按鼻夹使其与鼻梁贴合,然后按住鼻夹。将口罩下端向下拉至下颌处,使折叠边完全展开。
- 3. 整理口罩佩戴效果,使口罩能罩住使用者的鼻、口至下颌并保证口罩的密闭性。

【运输贮存】运输工具应清洁卫生、隔离火源。本产品应存放在干燥阴凉处,注意防水,避免阳光直射,严禁与有毒有害物质共同存放。本产品应贮存在阴凉干燥,清洁、避光、无腐蚀性气体、通风良好的室内。

#### 4.7签所用的图形符号说明】

STERILE	无菌			
STERILEEO	经环氧乙烷灭菌			
(2)	不得二次使用			
<b>©</b>	包装破损禁止使用			

#### 【生产批号】

【生产日期】

【失效日期】

其他内容详见说明书。

#### 中华人民共和国医疗器械注册证

注册证编号: 鲁械注准 20192140064

注册人名称	山东朱氏药业集团有限公司
注册人住所	单县开发区樊楼路南
生产地址	山东单县经济技术开发区
代理人名称	("进口医疗器械适用")
代理人住所	("进口医疗器械适用")
产品名称	一次性使用医用外科口罩
型号、规格	17.5cm×9.5cm
结构及组成	由表层、中间层、底层、口罩带、鼻夹组成。表层材料为 卫生级聚丙烯价粘布、中间层材料为聚丙烯喷丝法制成的 高效过滤熔喷布、底层材料为卫生级聚丙烯仿粘布、口罩 带为涤纶线和少量氨纶线针织而成、鼻夹为可弯折可定型 的聚丙烯制成。
适用范围	供临床医务人员在有创操作过程中風帶,覆盖住使用者的 口、鼻及下颌,为防止病原体微生物、体液、颗粒物等的 直接透过提供物理屏障。
附件	注册产品技术要求: 鲁械注准 20192140064
其他内容	
备注	原《医疗器械分类目录》产品分类编码: II 类: 6864 医用卫生材料及敷料

由批無门, 山东省食品药品监督管理局









# PHOTOCATALYTIC FACE MASK

(PHOTOCATALYST PATENTED TECHNOLOGY)

**WE ARE AN AUTHORIZED AGENT FOR** 



carestar.com.sg





# Patented Technology

# ENOVATA PHOTOCATALYTIC MASKS SERIES










# PATENTED TECHNOLOGY

# PATENTED PHOTOCATALYTIC TECHNOLOGY



- Decomposing 99% of harmful substances
- ■Sterilization and Purification
- ■Anti-haze, Anti-allergy, Safe and Harmless
- ■Latest technology: photocatalyst response to visible light (555nm)
- Producing Oxygen Anions, Anti-ultraviolet





CO<sub>2</sub> + H<sub>2</sub>O for order enquiries contact: sales@carestar.com.sg




# THE 3D PHOTOCATALYTIC FACE MASK

### PHOTOCATALYTIC 3D FACE MASK

### 3D MASK FOR CHILDREN





### 3D MASK FOR ADULTS





■ Photocatalytic 3D masks for adutls (5 pieces)



for order enquiries contact: sales@carestar.com.sg





# PHOTOCATALYTIC ADULT FACE MASK

### PHOTOCATALYTIC FACE MASK FOR ADULTS









■ Photocatalytic masks for adults (10 pieces) PINK

■ Photocatalytic masks for adults (10 pieces) WHITE ■ Photocatalytic masks for adults (10 pieces) BLUE









# PHOTOCATALYTIC KIDS FACE MASK

### PHOTOCATALYTIC FACE MASK FOR KIDS



■ Photocatalytic masks for kids (10 pieces) PINK



■ Photocatalytic masks for kids (10 pieces) BLUE



for order enquiries contact: sales@carestar.com.sg





# CERTIFICATIONS

### FDA APPROVED



					50.00	11.90907.3
京 報 章 遊覧工一 西京 5 6 支持 16 対象等官 対象性 平成23年 6月29日代 平成23年 7月1	ten m rrnnce ert.		6 T	95°20' 000-0000 x0 00000x 27 000-0000 x0	アンテス ISEN	BY 10.76
		- 4				-
MARKS No. 16 No.		-	5.80 R	100	pa.	45
D DESTRUCTION	80	9929	KWRIE.	LEXE	10.0	168
© (801.75-18)		SECUE	12×W	LOOF	_	_
RMS RESISES	0	MKEN		D RAKEN	KAKE	







# HIGH QUALITY & HIGHLY RECOMMENDED



# COVID-19 TEST KIT sensing.self

(COLLOIDAL GOLD METHOD)

WE ARE AN AUTHORIZED AGENT FOR sensing.self



carestar.com.sg



# 10 MINUTES DETECTION TIME

- >No lab visits, no doctors
- >Just one finger prick of blood


Very Cost Effective Solution





**ICMR Certified** 





European CE certified




### **Detection Period**

# 10 MINUTES

- >Easy operation without requirement of any Doctor or Professional Nurse
- >No special equipment storage and transportation conditions required
- > Works with whole blood, serum, and plasma
- >Tests for 2 antibodies IgM and IgG simultaneously
- > Instant Field screening

92% + ACCURACY



# Certification

- Certified by accredited CE
- FDA EUA Submitted Under Review





**European CE certified** 



ICMR Certified, National Institute Of Virology - India




### **CE & FDA CERTIFICATION**











#### Comparative Test Report

#### SARS-CoV-2 IgM Ab Rapid Test Vs PCR

(Immunochromatographic)

#### 1. Method

In this trial, 1300 clinical samples were selected. There were 300 positive samples and 1000 negative samples.

The SARS-CoV-2 IgM Ab rapid test and the SARS-CoV-2 PCR test were detected simultaneously, and the positive coincidence rate, negative coincidence rate, and total coincidence rate were calculated.

#### 2. Result

- (1) 300 cases of positive samples confirmed by Nucleic Acid Test (RT-PCR): tested with SARS-CoV-2 IgM Ab rapid test, 246 cases were positive, 54 cases were negative.
- (2) 1000 cases of negative samples confirmed by Nucleic Acid Test (RT-PCR): tested with SARS-CoV-2 IgM Ab rapid test, 960 cases were negative, 40 cases were positive.

#### 3. Analysis

(1) Results statistics table

SARS-CoV-2	PCI	Total	
IgM Ab — Rapid Test	Positive	Negative	1000
Positive	246	40	286
Negative	54	960	1014
Total	300	1000	1300

(2) Analysis of coincidence rate of SARS-CoV-2 IgM Ab rapid test and PCR test in serum samples

Positive coincidence rate=246/ (246+54) x 100%=82% (Sensitivity)
Negative coincidence rate=960/ (40+960) ×100%=96% (Selectivity)
Total coincidence rate= (246+960) / (246+54+40+960) ×100%=92.8% (Accuracy)

#### 4. Conclusion

SARS-CoV-2 IgM Ab rapid test and PCR test positive coincidence rate (Sensitivity) of 82%, negative coincidence rate (Selectivity) of 96%, total coincidence rate (Accuracy) of 92.8%.



#### **Comparative Test Report**

SARS-CoV-2 IgG Ab Rapid Test (Immunochromatographic)

#### 1. Method

In this trial, 1300 clinical samples were selected. There were 300 positive samples and 1000negative samples.

The SARS-CoV-2 IgG Ab rapid test and the SARS-CoV-2 PCR were detected simultaneously, and the positive coincidence rate, negative coincidence rate, and total coincidence rate were calculated.

#### 2. Result

- (1) 300 cases of positive samples confirmed by PCR Test: tested with SARS-CoV-2 IgG Ab rapid test, 279 cases were positive, 21 cases were negative.
- (2) 1000 cases of negative samples confirmed by PCR Test: tested with SARS-CoV-2 IgG Ab rapid test, 975 cases were negative, 25 cases were positive.

#### 3. Analysis

#### (1) Results statistics table

SARS-CoV-2	PCF	Total	
IgG Ab — Rapid Test	Positive	Negative	
Positive	279	25	304
Negative	21	975	996
Total	300	1000	1300

(2) Analysis of coincidence rate of SARS-CoV-2 IgG Ab rapid test and PCR test in serum samples

Positive coincidence rate=279/ (279+21) ×100%=93% (Sensitivity)

Negative coincidence rate=975/ (25+975) ×100%=97.5% (Specificity)

Total coincidence rate= (279+975) / (279+21+25+975) ×100%=96.5% (Accuracy)

#### 4. Conclusion

SARS-CoV-2 IgG Ab rapid test and PCR test positive coincidence rate (Sensitivity) of 93%, negative coincidence rate (Specificity) of 97.5%, total coincidence rate of 96.5% (Accuracy).



#### 5. Cross Reactivity Study:

Specimens which tested positive with following various agents from patients were investigated with SARS-CoV-2 IgM Ab Rapid Test (Lateral Flow Method). The results showed no cross reactivity.

P	arainfluenza virus antibody
	Influenza A antibody
	Influenza B antibody
Ch	lamydia pneumonia antibody
Мус	oplasma pneumoniae antibody
	Adenovirus antibody
Resp	iratory syncytial virus antibody
H	lepatitis B surface antibody
9	Hepatitis C virus antibody
Tr	eponema pallidum antibody
	HIV antibody
	EB virus antibody
	Measles virus antibody
- 3	Cytomegalovirus antibody
Е	nterovirus type 71 antibody
	Mumps antibody
Varice	ella-zoster virus positive sample

#### 6. Interferences Study:

The test result of SARS-CoV-2 IgM Ab Rapid Test (Lateral Flow Method) does not interfere with the substance at the following concentration:

Substance	Concentration
Bilirubin	250 umol/L
Hemoglobin	9 g/L
Triglyceride	15 mmol/L
Rheumatoid factors	80 fU/mL
Antinuclear antibody (ANA) titer	1:240
Anti-mitochondrial antibody (AMA)	80 U/mL
Mouse IgG	1000 ug/ml



# COVID-19 TEST KIT (V2)

(COLLOIDAL GOLD METHOD)

carestar.com.sg





### **COLLOIDAL GOLD METHOD**

#### nCoV Test Kit (Colloidal Gold Method)

Common name: Novel coronavirus antibody detection kit (colloidal gold method)

#### Intended Use

The kit is intended for the vitro qualitative determination of IgG and IgM antibodies of the novel coronavirus in human serum, plasma or blood.

Coronavirus (CoV) belongs to the Coronaviridae, and is civided into four genera: alpha, beta, gamma and delta.

Only the alpha and beta genera are pathogenic to mammals. The gamma genus mainly causes avian infections. CoV is mainly transmitted through direct contact with secretions or through aerosols and droplets. There is also avidence that it can be transmitted through the fecal-oral route.

So far, there are 7 human coronaviruses (HCoV) that cause human respiratory diseases: HCoV-229E, HCoV-OC43, SARS-CoV, HCoV-NL63, HCoV-HKU1, MERS-CoV and now this new coronaviruse (2019) is an important pathogen of human respiratory infections.

This new coronavirus (2019), now commonly called the "novel coronavirus" or CoVID-19 was discovered due to the Wuhan viral pneumonia cases in 2019. The clinical manifestations are systemic symptoms such as fever and fatigue, accompanied by dry cough and dyspnea, etc., which can rapidly develop into severe pneumonia, with respiratory failure. A distress syndrome, with septic shock, multiple organ failure, severe acid-base metabolism disorders, etc. is equally life-threatening.

#### Principle of the method

The kit uses immunochromatography and the test card is contained.

- Colloidal gold-labeled recombinant novel coronavirus antigen and quality control antibody gold markers;
- 2) A nitrocellulose membrane fixed with two detection lines (G and M lines) and one quality control line (C line). The M line is immobilized with a monoclonal anti-human IgM antibody for detecting a new coronavirus IgM antibody; the G line is immobilized with a monoclonal anti-human IgG antibody for a novel coronavirus IgG antibody; the C line is immobilized with a quality control antibody. When an appropriate amount of the test sample is added to the sample hole of the test card, the sample will move forward along the test card under capillary action. If the sample contains an IgM antibody, the antibody will bind to the colloidal gold-labeled novel coronavirus antigen, and the immune complex will be captured by the anti-human IgM antibody immobilized on the membrane to form a purple-red M line, showing that the new coronavirus IgM antibody is positive.

If the sample contains an IgG antibody, the antibody will bind to the colloidal gold-labeled novel coronavirus antigen, and the immune complex will be captured by the reagent immobilized on the membrane to form a purple red G line, indicating that the new coronavirus IgG antibody is positive. If the test lines G and M are

not colored, a negative result is displayed. The test card also contains a quality control line C. The fuchsia quality control line C should appear regardless of whether a test line appears. The QC line is the color band of the QC antibody immune complex. If the quality control line C does not appear, the test result is invalid, and the sample needs to be tested again with another test card.

#### Main ingredient

- 1. One-time test card
- 2. Sample Diluent (1 bottle, 1 mL / bottle)
- 3. user's manual

#### Storage conditions and validity

- Store in a dry environment at 2-30 °C, protected from light.
- After opening the inner package, the test card will become invalid due to moisture absorption if not used within 1 hour.
- 3. Valid for 18 months if stored correctly.

#### Sample collection, handling and storage

- Suitable for human serum, plasma or whole blood samples, including plasma or whole blood samples prepared by commonly used anticoagulants (EDTA, heparin, sodium citrate).
- 2. The samples should be collected and tested immediately. If the test cannot done detected immediately, the serum and plasma samples to be tested can be stored at 2 8 °C for 5 days. For long-term storage, store at -20 °C. Avoid repeated freeze-thaw cycles. Anticoagulated whole blood samples should not be stored for more than 72 hours at room temperature; not more than 7 days at 2-8 °C.
- Before testing, slowly return the refrigerated or frozen samples to room temperature and mix them carefully. When clearly visible particulate matter is present in the sample, it should be centrifuged to remove sediment before testing.
- If the sample contains a large amount of lipid, hemolysis or turbidity, please do not use it, as this can affect the reading of the result.

#### Testing method

- If the sample has been stored refrigerated or frozen, remove the test sample and the required reagents from the storage conditions and equilibrate to room temperature (15 - 30 °C). After thawing and equilibration, mix the samples thoroughly before testing.
- When preparing to test, open the aluminum foil bag along the tear line. Remove the test card and lay it flat on a horizontal table.
- 3. Mark the sample number on the test card.
- 4. Use a sample gun or a dropper to draw 10 μl of the test sample (serum, plasma or whole blood sample) from the sample tube and immediately add 2 drops (about 70 ~ 100 μL) of sample into the sample well. Dilute the solution as shown below and ensure that no air bubbles are generated during the operation.
- 5. Set the time counter for interpretation of results in 15 minutes




Note: Do not read the results later than that initial 15 minutes. After





#### POSITIVE RESULT IF

ANY PEMUTATION LINES APPEAR ON C/G/M




# **15-MIN INSTANT RESULTS**

COVID-19 ESSENTIALS



# 15-MIN INSTANT RESULTS





# **SEALED PACKAGING**







## **OUTER BOX**







# **HOW TO USE COVID-19 TEST KIT VIDEO**






# HOW TO READ TEST RESULT?



#### Interpretation of test results

 Negative results: If only the quality control line C appears, and the detection lines G and M do not show color, it means that no novel coronavirus antibody is detected and the result is negative (see the figure below).



#### 2. Positive results:

2.1 If both the quality control line C and the detection line M appear, it means that the novel coronavirus IgM antibody is detected, and the result is that the IgM antibody is positive (see the figure below).



2.2 If both the quality control line C and the detection line G appear, it indicates that the novel coronavirus IgG antibody is detected, and the result is positive for IgG antibody (see the figure below).



2.3 If both the quality control line C and the detection lines G and M appear, it indicates that the novel coronavirus IgG and IgM antibodies have been detected, and the results are positive for IgG and IgM antibodies (as shown below)



Invalid result: If the quality control line C is not observed, it will be invalid regardless of whether the detection line is displayed (see the figure below), and the test should be performed again.







### CERTIFIED BY MEDICINE & HEALTH AUTHORITY

# 医疗器械生产许可证

REPORTED BY A THE REPORT OF THE PROPERTY OF THE PORTED BY A DESCRIPTION OF THE PORTED BY A DE

许可证编号: 黔食药监械生产许20190004号

企业名称:贵州立知健生物科技有限公司 生产地址:贵州省贵阳市乌当区贵州大健康医药产业

智汇云锦孵化基地 A1 栋 1 层

法定代表人: 张远波 生产范围:II类: 22-04-免疫分析设备,6840-体外诊

断试剂

企业负责人: 张远波

主 所:贵州省贵阳市乌当区贵州大健康医发证部门:贵州省药品监督管理局

药产业智汇云锦孵化基地 B8 栋 17 层

有效期限:至 2024年 09月 28日 发证日期: 2019年 09月 29日

DEN OF DESCRIPTION OF THE PROPERTY OF THE PROP

# COVID-19 PCR KIT


ProTect™

carestar.com.sg





# WHY PCR KIT? (SUITABLE FOR HOSPITAL & LAB USE)







# COVID-19 PCR KIT

### MADE IN SINGAPORE



#### **Intended Use**

The ProTect™ Coronavirus Disease 2019 (COVID-19) RT-qPCR kit by JN Medsys provides all necessary reagents for the *in vitro* qualitative detection of the SARS-CoV-2 virus from upper respiratory nasopharyngeal specimens. The test is compatible with the US CDC protocol, targeting the SARS-CoV-2 N1, N2 and N3 genes and the human RNase P control gene.

This assay has received Provisional Authorisation from the Health Sciences Authority in Singapore

# IVD

#### **Product Information**

Test Principle	One-step RT-qPCR (TaqMan®-based detection)
Targets	One-step RT-qPCR (TaqMan®-based detection)  N1, N2, N3 (SARS-CoV-2 virus) and RNase P (Human)
Number of Tests	50/ kit (Cat No. 10024) or 100/kit (Cat. No. 10027)
Compatible Specimen Type	Upper respiratory nasopharyngeal specimens (i.e. nasopharyngeal swabs)
Limit of Detection^	10 copies RNA per reaction (N1, N2, N3)
Precision^	<2%
Specificity	Detects only SARS-CoV-2 based on in silico sequence validation

<sup>^</sup>Validated on QuantStudio™ 3 Real-Time PCR System (Applied Biosystem)

#### Reagents Supplied

Each kit provides reagents sufficient for performing 50 tests and consists of the following:

- 1. ProTect™ one-step RT-qPCR reagent
- 2. Ready-to-use primer and probe mixes for N1, N2, N3 and RNase P
- 3. Nuclease-free water
- 4. Positive Controls

Ordering Information				
Product Name	Description	Catalogue Number		
ProTect™ COVID-19 RT-qPCR Kit	50 Tests	10024		
ProTect™ COVID-19 RT-qPCR Kit	100 Tests	10027		





#### INTENDED USE

The ProTect™ Coronavirus Disease 2019 (COVID-19) RT-qPCR kit by JN Medsys provides all necessary reagents for the *in vitro* qualitative detection of SARS-CoV-2 from upper respiratory nasopharyngeal specimens. The test is compatible with the US CDC protocol, targeting SARS-CoV-2 N1, N2 and N3 genes and the human RNase P control gene.

This assay has received Provisional Authorisation from the Health Sciences Authority in Singapore



#### KIT FEATURES

Test Principle	One-step RT-qPCR (TaqMan®-based detection)
Targets	N1, N2, N3 (SARS-CoV-2) and RNase P (Human)
Number of Tests	50/kit (Cat. No. 10024) or 100/kit (Cat. No. 10027)
Compatible Specimen Type	Upper respiratory nasopharyngeal specimens (i.e. nasopharyngeal swabs
Limit of Detection^	10 copies RNA per reaction (for N1, N2, N3)
Precision^	<2%
Specificity	Detects only SARS-CoV-2 based on in silico sequence validation

<sup>^</sup> Validated on QuantStudio™ 3 Real-Time PCR System (Applied Biosystems)

#### Limit of Detection (LoD)

LoD studies determine the lowest detectable concentration of SARS-CoV-2 at which approximately 95% of all replicates test positive. The LoD was determined to be 10 copies/reaction based on limiting dilution studies. The results are summarised as follow:

Target	Concentration	Number of replicates tested positive	Mean Ct	Standard Deviation	Relative Uncertainty (%)	
N1	10 copies/reaction	20/20	34.27	0.36	1.06	
N2	10 copies/reaction	20/20	33.16	0.54	1.64	
N3	10 copies/reaction	20/20	34.35	0.30	0.89	

<sup>\*</sup> Relative uncertainty = Standard deviation/Mean

#### Precision

Precision studies determine the reproducibility and robustness of the test. Three independent tests were conducted for N1, N2 and N3 assays in 10 replicates for each test. The results demonstrate that these assays achieved a relative uncertainty of <2%.

Test	N1			N1 N2			N3				
	Mean Ct	Standard Deviation	Relative Uncertainty (%)	Mean Ct	Standard Deviation	Relative Uncertainty (%)	Mean Ct	Standard Deviation	Relative Uncertainty (%)		
1	25.47			26.52			25.71		100000		
2	24.76	0.41	0.41 1.64%	25.96	0.47	0.47	0.47	1.79%	25.77	0.07	0.25%
3	25.49	3723707077		26.90	S 690220.	20mo-400304	25.84	198800	18/1/6/19/9		

<sup>\*</sup> Relative uncertainty = Standard deviation/Mean

# PCR KIT SPECIFICATION

#### KIT CONTENTS

Each kit includes reagents sufficient to perform 50 tests (Cat No. 10024) or 100 tests (Cat No. 10027). Each test includes 4 separate RT-qPCR assays, which target the N1, N2, N3 and RNase P genes, respectively.

Reagents Supplied	50 Tests (10024)	100 Tests (10027)	
	Volume (µL)	Volume (µL)	
Box 1 (Mastermix)	,,,,,		
ProTect <sup>™</sup> Probe qPCR Mastermix (2X)	2000	4000	
ProTect™ RT Mix (50X)	200	200	
Nuclease Free Water	1000	2000	
Box 2 (Primer/Probe Mix, Positive Controls)			
N1 Primer & Probe Mix (FAM)	85	170	
N2 Primer & Probe Mix (FAM)	85	170	
N3 Primer & Probe Mix (FAM)	85	170	
RNase P Primer & Probe Mix (FAM)	85	170	
COVID-19 Positive Control^*	35	70	
RNase P Positive Control^	15	30	

<sup>^</sup>Sufficient for 10 tests (10024) and 20 tests (10027), dilute 5X using TE Buffer (pH8) prior to use

#### STORAGE AND STABILITY

The ProTect™ COVID-19 RT-qPCR kit should be stored at -20°C upon receipt. Avoid repeated freezing and thawing of kit contents. The kit is stable through the expiry date indicated on the kit label.

#### **GENERAL CONSIDERATIONS**

- Laboratory personnel should be familiar with the protocol and instruments used, and are required to wear appropriate personal protective equipment (e.g. gowns, gloves, eye protection) when performing the tests
- 2. Use only aerosol-resistant pipette tips
- Do not open tube strips or reaction plates after amplification is completed to minimize risks of contaminating subsequent reactions with the amplified product
- Clean and decontaminate all work surfaces, pipettes, equipment prior to use using cleaning agents against RNase

#### **EXPERIMENTAL SETUP**

- Thaw reagents at room temperature and maintain reagents on ice when thawed. Mix reagents gently and briefly centrifuge to collect contents at the bottom of the tubes.
- 2. Prepare each reaction mix as shown in the table below:

<sup>\*</sup> The COVID-19 Positive Control is a plasmid consisting of N1, N2 and N3 target sequences and serves as a control for the N1. N2 and N3 tests.

<sup>+</sup> The RNase P Positive Control is a plasmid consisting of the RNase P target sequence and serves as a control for the RNase P test.



# PCR KIT SPECIFICATION

No.	Reagents	Volume (μL)
1	ProTect <sup>™</sup> Probe qPCR Mastermix (2X)	10
2	ProTect <sup>™</sup> RT Mix (50X)	0.4
3	Primer & Probe Mix for N1, N2, N3 or RNase P	1.5
4	Nuclease free water	3.1
5	RNA Sample/Positive control	5
	Total Vol	20

<sup>!</sup> Positive and no template controls should be run concurrently with all test samples

- 3. Pipette 20  $\mu$ L of the reaction mix into the required reaction tube strip or 96-well plate.
- 4. Centrifuge to collect contents at the bottom of the tube strip/plate.
- Transfer tube strip/plate to qPCR instrument and perform one-step RT-qPCR according to the following protocol. Fluorescence data for FAM should be collected during the 55°C annealing & extension step.

Step	Cycle	Temperature	Time
Reverse Transcription	1	45°C	15 min
Reverse Transcriptase Inactivation & DNA Polymerase Activation	1	95°C	2 min
Denaturation	40	95°C	3 sec
Annealing & Extension	40	55°C	30 sec

#### DATA ANALYSIS AND INTERPRETATION

- 1. No Template Control No fluorescence signal should be detected
- 2. Positive Control Fluorescence signal should be detected with Ct value below 30
- 3. Results for the respective targets may be interpreted as follow:

N1	N2	N3	RNase P	Outcome
+	+	+	<u>+</u>	SARS-CoV-2 detected
Any two ou	ut of three targets	positive	<u>+</u>	SARS-CoV-2 detected
	<b>3</b> 0	1021	+	SARS-CoV-2 not detected
If only one	of these targets is	positive	<u>+</u>	Inconclusive result. Repeat test
-	157	-	9.50	Invalid result. Repeat test

<sup>1</sup> Dilute Positive Controls 5X using TE Buffer (pH8) prior to use



### APPROVED BY HEALTH & SCIENCE AUTHORITY OF SINGAPORE

Health Sciences Authority 11 Outram Road Singapore 169078 Tel: 65 6213 0838 Fax: 65 6213 0749 Website: www.hsa.gov.sg







25 March 2020

JN Medsys Pte Ltd 217 Henderson Road #02-08 Singapore 159555

Dear Low Huiyu

#### RE: STATUS OF SUPPLY OF MEDICAL DEVICES IN SINGAPORE

This letter serves to confirm that the following medical device product(s) have been issued Provisional Authorisation for supply in Singapore and may be exported from Singapore.

No.	Device Proprietary Name	Intended Use		
1	ProTect <sup>™</sup> COVID-19 RT-qPCR Kit (10024) (10027)	The ProTect™ Coronavirus Disease 2019 (COVID-19) RT-qPCR kit by JN Medsys provides all necessary reagents for the in vitro qualitative detection of SARS-CoV-2 from upper respiratory nasopharyngeal specimens. The test is targeting SARS-CoV-2 N1, N2 and N3 genes and the human RNase P control gene.		

Product Owner:

JN Medsys Pte Ltd 217 Henderson Road

#02-08

Singapore 159555

Manufacturing Site:

JN Medsys Pte Ltd

217 Henderson Road #02-08 Singapore 159555



Page 1 of 2

- 2. The medical device product(s) may be supplied to the healthcare institutions, private hospitals. medical clinics or clinical laboratories licensed under the PHMC Act (Cap. 248) for use on their patients.
- 3. The medical device product(s) may be exported out of Singapore subject to the duties and obligations as stipulated in the Health Products Act and the Health Products (Medical Devices) Regulation 2010.
- 4. The confirmation above is subject to the manufacturer's activities conforming to the ISO 13485

Yours sincerely,

DR LAKSHMIDEVI BALAKRISHNAN SENIOR REGULATORY SPECIALIST For GROUP DIRECTOR

HEALTH PRODUCTS REGULATION GROUP **HEALTH SCIENCES AUTHORITY** 



Page 2 of 2





# INFRARED THERMOMETER

carestar.com.sg





### FOREHEAD SCANNING







# NFRARED THERMOMETER

### **BOX DIMENSION**







# CE CERTIFIED



Registration No.: A2003100-C01-R01

Applicant : Shenzhen Yostand Technology Co., Ltd.

East Factory, 10th Floor, Mingzhuo Building, Mingzhuo Xingye Science and Technology Park, Gongming Street, Gongming Street, Guangming

New District, Shenzhen, China

Product : Infrared Thermometer

Model No. : YS-ET0

Address

Trademark : 母亲 yostand

The submitted products have been tested by us with the listed standards and found in compliance with the following European Directives:

The EMC Directive 2014/30/EU

EN 61000-6-3:2007 + A1:2011

EN 61000-6-1:2007

The tests were performed in normal operation mode, the test results apply only to the particular sample tested and to the specific tests carried out. This certificate applies specifically to the sample investigated in our test reference number only.

The CE markings as shown below can be affixed on the product after preparation of necessary technical documentation.

Other relevant Directives have to be observed.

(6

Certified by

March 13, 2020





Shenzhen Alpha Product Testing Co., Ltd. Building i, No.2, Lixin Road, Fuyong Street, Bao'an District, 518103, Shenzhen City, Guangdong Province, P.R. China Website:http://www.a-lab.cn Email:service@a-lab.cn

0010175



### **CERTIFICATION FROM MEDICAL & HEALTH AUTHORITY**

# 医疗器械生产许可证

许可证编号:粤食药监械生产许20010144号

企业名称: 深圳市一讯达科技有限公司

法定代表人: 姜红军

企业负责人: 姜红军

所: 深圳市光明新区公明街遊楼村社区第一 工业区明卓兴业科技园明卓大厦十楼东

厂房

效期限: 至 2025 年 03 月 09 日

生产地址:深圳市光明新区公明街道楼村社区第一 工业区明卓兴业科技园明卓大厦土楼东

厂房

生产范围: 11类6826物理治疗及康复设备

发证部门:广东省食品药品监督第

发证日期:

2020

03 月 (0





# NFRARED THERMOMETER

#### APPROVAL FROM AUTHORITY ON MEDICAL GRADE PRODUCTS

### 深圳市市场监督管理局

# 关于深圳市一讯达科技有限公司申请第二类医疗器械应急审批的情况说明


深圳市一讯达科技有限公司为我市生产企业、成立于 2017年,位于深圳市光明新区公明街道楼村申请第一工业区 明卓兴科技园明卓大厦十楼东厂房、法人代表: 姜红军。该 企业现有拟用于本次申请品种实际生产面积 1000 m°。员工 50人、主要生产红外恶应车载支架、无线充、充电器、充电 宝等数码产品。为满足抗击新冠肺炎疫情物资保障所需。该 企业申请非接触式红外体温计产品进入应急审批程序,有关 情况如下:

- 一、拟申请产品名称: 非接触式红外体温计,结构组成: PCBA, 壳料,红外传感器等,适用范围:工厂、学校、医院、社区、商傭、家庭等单位人员的温度检查,执行标准: GB/T 21417,1-2008《医用红外体温计第1部分:耳腔式》、GB 9706.1-2007《医用电气设备第1部分:安全通用要求》。属于当前疫情防控急需物资。
- 二、该产品的主要生产设备已经安装到位,主要原材料 已订购;投产后,日产能1000个/天。
- 三、当前,申请产品及其同类产品市场供应不足,在疫情防控期间确需应急采购。

特此说明。

深圳市市场监督管理局 2020年3月10日







#### 第二类医疗器械经营备案凭证

各案编号。粤源食药效械经营备 20201475 号

企业名称	探刺市一讯达科技有限公司	
法定代表人	美红军	
企业负责人	美红军	
经营方式	似本表情	
Œ M	深圳市光明新区公明则道楼村社区第一工业区明卓兴业科技提明辛大厦十楼 东广岛	
经营场所	提到市先明新区公明奥道楼村社区第一工业区明卓共业科技园明卓大厦十楼 系扩 第	
库房地址	採助方式明新区公明供道楼村社区第一工业区明卓兴业科技国明卓大厦十楼 东广岛	
经常范围	2002年分表目录(二页)。6501、6502、6503、6504、6505、6506、6507、6508、6500、6510、6512、6513、6515、6516、6500、6505、6506、6500、6510、6512、6513、6513、6515、6516、6500、6621、6522、6523、6523、6523、6523、6523 (652)	







carestar.com.sg

COVID-19 ESSENTIALS